ECG AI-Guided Screening for Low Ejection Fraction (EAGLE): Rationale and design of a pragmatic cluster randomized trial

Xiaoxi Yao, Rozalina G. McCoy, Paul A. Friedman, Nilay D. Shah, Barbara A. Barry, Emma M. Behnken, Jonathan W. Inselman, Zachi I. Attia, Peter A. Noseworthy

Research output: Contribution to journalArticle

Abstract

Background: A deep learning algorithm to detect low ejection fraction (EF) using routine 12-lead electrocardiogram (ECG) has recently been developed and validated. The algorithm was incorporated into the electronic health record (EHR) to automatically screen for low EF, encouraging clinicians to obtain a confirmatory transthoracic echocardiogram (TTE) for previously undiagnosed patients, thereby facilitating early diagnosis and treatment. Objectives: To prospectively evaluate a novel artificial intelligence (AI) screening tool for detecting low EF in primary care practices. Design: The EAGLE trial is a pragmatic two-arm cluster randomized trial (NCT04000087) that will randomize >100 clinical teams (i.e., clusters) to either intervention (access to the new AI screening tool) or control (usual care) at 48 primary care practices across Minnesota and Wisconsin. The trial is expected to involve approximately 400 clinicians and 20,000 patients. The primary endpoint is newly discovered EF ≤50%. Eligible patients will include adults who undergo ECG for any reason and have not been previously diagnosed with low EF. Data will be pulled from the EHR, and no contact will be made with patients. A positive deviance qualitative study and a post-implementation survey will be conducted among select clinicians to identify facilitators and barriers to using the new screening report. This trial will examine the effectiveness of the AI-enabled ECG for detection of asymptomatic low EF in routine primary care practices and will be among the first to prospectively evaluate the value of AI in real-world practice. Its findings will inform future implementation strategies for the translation of other AI-enabled algorithms.

Original languageEnglish (US)
Pages (from-to)31-36
Number of pages6
JournalAmerican Heart Journal
Volume219
DOIs
StatePublished - Jan 2020

Fingerprint

Artificial Intelligence
Electrocardiography
Primary Health Care
Electronic Health Records
Early Diagnosis
Learning

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

ECG AI-Guided Screening for Low Ejection Fraction (EAGLE) : Rationale and design of a pragmatic cluster randomized trial. / Yao, Xiaoxi; McCoy, Rozalina G.; Friedman, Paul A.; Shah, Nilay D.; Barry, Barbara A.; Behnken, Emma M.; Inselman, Jonathan W.; Attia, Zachi I.; Noseworthy, Peter A.

In: American Heart Journal, Vol. 219, 01.2020, p. 31-36.

Research output: Contribution to journalArticle

@article{a920d13e8fb74ab3b07ab3b9c8acef20,
title = "ECG AI-Guided Screening for Low Ejection Fraction (EAGLE): Rationale and design of a pragmatic cluster randomized trial",
abstract = "Background: A deep learning algorithm to detect low ejection fraction (EF) using routine 12-lead electrocardiogram (ECG) has recently been developed and validated. The algorithm was incorporated into the electronic health record (EHR) to automatically screen for low EF, encouraging clinicians to obtain a confirmatory transthoracic echocardiogram (TTE) for previously undiagnosed patients, thereby facilitating early diagnosis and treatment. Objectives: To prospectively evaluate a novel artificial intelligence (AI) screening tool for detecting low EF in primary care practices. Design: The EAGLE trial is a pragmatic two-arm cluster randomized trial (NCT04000087) that will randomize >100 clinical teams (i.e., clusters) to either intervention (access to the new AI screening tool) or control (usual care) at 48 primary care practices across Minnesota and Wisconsin. The trial is expected to involve approximately 400 clinicians and 20,000 patients. The primary endpoint is newly discovered EF ≤50{\%}. Eligible patients will include adults who undergo ECG for any reason and have not been previously diagnosed with low EF. Data will be pulled from the EHR, and no contact will be made with patients. A positive deviance qualitative study and a post-implementation survey will be conducted among select clinicians to identify facilitators and barriers to using the new screening report. This trial will examine the effectiveness of the AI-enabled ECG for detection of asymptomatic low EF in routine primary care practices and will be among the first to prospectively evaluate the value of AI in real-world practice. Its findings will inform future implementation strategies for the translation of other AI-enabled algorithms.",
author = "Xiaoxi Yao and McCoy, {Rozalina G.} and Friedman, {Paul A.} and Shah, {Nilay D.} and Barry, {Barbara A.} and Behnken, {Emma M.} and Inselman, {Jonathan W.} and Attia, {Zachi I.} and Noseworthy, {Peter A.}",
year = "2020",
month = "1",
doi = "10.1016/j.ahj.2019.10.007",
language = "English (US)",
volume = "219",
pages = "31--36",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - ECG AI-Guided Screening for Low Ejection Fraction (EAGLE)

T2 - Rationale and design of a pragmatic cluster randomized trial

AU - Yao, Xiaoxi

AU - McCoy, Rozalina G.

AU - Friedman, Paul A.

AU - Shah, Nilay D.

AU - Barry, Barbara A.

AU - Behnken, Emma M.

AU - Inselman, Jonathan W.

AU - Attia, Zachi I.

AU - Noseworthy, Peter A.

PY - 2020/1

Y1 - 2020/1

N2 - Background: A deep learning algorithm to detect low ejection fraction (EF) using routine 12-lead electrocardiogram (ECG) has recently been developed and validated. The algorithm was incorporated into the electronic health record (EHR) to automatically screen for low EF, encouraging clinicians to obtain a confirmatory transthoracic echocardiogram (TTE) for previously undiagnosed patients, thereby facilitating early diagnosis and treatment. Objectives: To prospectively evaluate a novel artificial intelligence (AI) screening tool for detecting low EF in primary care practices. Design: The EAGLE trial is a pragmatic two-arm cluster randomized trial (NCT04000087) that will randomize >100 clinical teams (i.e., clusters) to either intervention (access to the new AI screening tool) or control (usual care) at 48 primary care practices across Minnesota and Wisconsin. The trial is expected to involve approximately 400 clinicians and 20,000 patients. The primary endpoint is newly discovered EF ≤50%. Eligible patients will include adults who undergo ECG for any reason and have not been previously diagnosed with low EF. Data will be pulled from the EHR, and no contact will be made with patients. A positive deviance qualitative study and a post-implementation survey will be conducted among select clinicians to identify facilitators and barriers to using the new screening report. This trial will examine the effectiveness of the AI-enabled ECG for detection of asymptomatic low EF in routine primary care practices and will be among the first to prospectively evaluate the value of AI in real-world practice. Its findings will inform future implementation strategies for the translation of other AI-enabled algorithms.

AB - Background: A deep learning algorithm to detect low ejection fraction (EF) using routine 12-lead electrocardiogram (ECG) has recently been developed and validated. The algorithm was incorporated into the electronic health record (EHR) to automatically screen for low EF, encouraging clinicians to obtain a confirmatory transthoracic echocardiogram (TTE) for previously undiagnosed patients, thereby facilitating early diagnosis and treatment. Objectives: To prospectively evaluate a novel artificial intelligence (AI) screening tool for detecting low EF in primary care practices. Design: The EAGLE trial is a pragmatic two-arm cluster randomized trial (NCT04000087) that will randomize >100 clinical teams (i.e., clusters) to either intervention (access to the new AI screening tool) or control (usual care) at 48 primary care practices across Minnesota and Wisconsin. The trial is expected to involve approximately 400 clinicians and 20,000 patients. The primary endpoint is newly discovered EF ≤50%. Eligible patients will include adults who undergo ECG for any reason and have not been previously diagnosed with low EF. Data will be pulled from the EHR, and no contact will be made with patients. A positive deviance qualitative study and a post-implementation survey will be conducted among select clinicians to identify facilitators and barriers to using the new screening report. This trial will examine the effectiveness of the AI-enabled ECG for detection of asymptomatic low EF in routine primary care practices and will be among the first to prospectively evaluate the value of AI in real-world practice. Its findings will inform future implementation strategies for the translation of other AI-enabled algorithms.

UR - http://www.scopus.com/inward/record.url?scp=85074666778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074666778&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2019.10.007

DO - 10.1016/j.ahj.2019.10.007

M3 - Article

AN - SCOPUS:85074666778

VL - 219

SP - 31

EP - 36

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

ER -